Business Context and Reporting Period
This Form 6-K is filed by PainReform Ltd. (PRF Technologies Ltd.) for the month of January 2026, dated January 7, 2026. The filing serves to update the U.S. Securities and Exchange Commission regarding the acquisition of LayerBio Inc. ("LayerBio"). The Company previously disclosed on July 10, 2025, its agreement to acquire 7,331,378 shares of LayerBio preferred stock, representing a 51% fully diluted ownership stake.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the text body. Instead, it references the following exhibits containing the financial data:
- Exhibit 99.1: Unaudited pro forma condensed combined financial statements for the six months ended June 30, 2025, and the year ended December 31, 2024.
- Exhibit 99.2: Audited financial statements of LayerBio for the years ended December 31, 2024, and 2023.
- Exhibit 99.3: Unaudited condensed financial statements of LayerBio for the six months ended June 30, 2025.
The filing explicitly states that the pro forma information does not necessarily reflect actual results had the acquisition occurred in prior periods nor does it indicate future results.
Material Changes
The primary material change disclosed is the execution of the Preferred Stock Purchase Agreement dated July 8, 2025, resulting in the Company's acquisition of a controlling 51% interest in LayerBio Inc. This filing updates the prior disclosure by providing the required pro forma and audited financial information associated with this transaction.
Guidance, Outlook, and Risks
The filing contains no specific forward-looking guidance, management commentary on future operations, or detailed risk factors beyond the standard disclaimer regarding pro forma financial information. The text notes that the pro forma data is unaudited and may not reflect actual future costs, expenses, or financial positions.
Investor Verification Checklist
- Review Exhibit 99.1 for the unaudited pro forma combined financial impact of the LayerBio acquisition.
- Examine Exhibit 99.2 and Exhibit 99.3 for LayerBio's standalone audited and unaudited financial performance.
- Verify the terms of the Preferred Stock Purchase Agreement referenced in the Prior 6-K (July 10, 2025) to understand the full scope of the 51% acquisition.
- Confirm the status of the acquisition closing, as the text references the transaction "at closing."